Case 1:14-cv-01239-GMS Document 3 Filed 09/25/14 Page 1 of 1 Page|D #: 46
`
`MW 12?! lRm'
`
`fréiflm
`
`T0.
`“
`"
`
`Mail Stay 8
`Dirt-ctur M the (LS. Yntenl and Trsuiemark ()fl'u:e
`l‘.(). flax N50
`Alexandria. V.-X 22313-I450
`
`
`
`Rl'Zi’DRT ON '1‘!-Iii
`FIEJNG OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRAfiE]\1;\R]{
`
`in (‘on1p3i-mwe mm 35 l}.S.(‘. §~; 290 '.-mdfnr £5 l$.S.(.‘. § I 1 lb you are iwrcby iid\‘l$‘st3(§ mm :1 mun zsctiun has hem
`flied in {IRS US. [)istric: Calm
`for the District of Delaware
`on the fi:uIim\/tug
`
`S Tl'i~$€kI§ll1*lT'k.‘il\X
`
`Er‘tllv;‘I¥l.~‘..
`
`(
`
`L___I
`
`flu’: pallmlt zuzliqm ivuvniw,-s 35 l,i.$LC. § 292.3:
`
`§)CL)C“K.EE.T N0.
`
`§’1..AEN T I FF
`CEPHALON, INC.
`
`lT.‘);\Tli H1,.E:.[L)
`9l25I2D14
`
`LJ.S. 1:133} RICTT‘ (‘CIURT
`for the District of Delaware
`
`I‘) E F RN [M T
`SANDOZ INC.
`
`
`
`
` ¥’.~’\TF.?~€'l“ OR I).~=\"H{ OF P2\‘T'E;\§T A . ,. . , , _. M _ _. ,
`
`
`
`
`
`
`
`
`
`TRM,mM,,\RK NU?
`“R .i.Rm.,/WMARK
`HULDLR OF PA] LNE {JR lR.»\DLMARl\
`
`1 8,791,270
`
`7x‘29¢'20‘l4
`
`CEPHALON, SNC.
`
`
`
`In the abuse
`
`cmnicd cane. me ihltmving gaulctltéw 1l'adLumurl«‘.{:¢) imw heax1 included:
`
`1).r‘\‘l’l-1 H\.'(“1.l,.’E‘)l‘I[)
`
`lY\‘(_'l,L.T)i7l) RY
`
`l‘.:‘\'H:.A‘-.”I‘ on
`
`l‘R;*\l..)E.:‘.“v1e\I-ll<; NU.
`(BY) UEl’UI'Y('L.1{RK
`
`In me uh-mv:
`
`eniidmi case. the ihilnwing clacasinzu has; hem rcmiered my judgexnelu isstxeai.
`
`DECK$103-‘JL?[K3E.3~1‘EN'T
`
`('l..l‘.RK
`
`(fopy 3~m~~«Up0Ia termination of action. mail {his copy 10 Director
`l—~ —~L.'p0n initiariun ofactima, mail this cop) to Uirxc-cmr
`([‘np_\
`(7np.\' 2 ----~L'p11Il filing duvcumem adding p:IIcnt{s). mail this copy to DiI*ectur
`Copy 4~«—~Caw file cop)‘
`
`AGILA ET AL - EXHIBIT 1004
`
`0001
`
`0001
`
`AGILA ET AL - EXHIBIT 1004
`
`

`
`’f‘RA[)F_.MARl(
`
`M‘; 12!”! IRc.‘\x fix Hf!)
`
`TU:
`
`Mail Stop 8
`Director of lhe LES. Patent and Trmieluurk Office
`PI). Box I450
`.-'\IexaudI'ia, VA 22353-1450
`
`REPORT 0355 THE
`FILING UR DETERIVIINATION OF AN
`ACTTIUN REGARDING A PATENT OR
`
`E I I6: ymi aw iicreby advised that -.1 mun actiun has been
`in (‘c>mpIi~.i.ncc mm 35 l;~5.('. 35 29L’! zmdiur ii I.i.S.('. {i
`Iiied in the (3.3,
`I)i.~'tri<:1 (‘nun
`for the DISITICI Of DEIBWBTe
`cm the Ihlimving
`
`B "I”i':u,Imn:»irk.s nr
`
`EI":«,1lcnL»‘.
`
`( E] iliv: pulunt zsciinn inm§w::‘ 35 I,I.‘.S.('. § 392.}:
`
`i‘)CiL“K[-VI‘ NU.
`
`i’I..e\INTIFF
`CEPHALON. INC,
`
`[“J,»'xTI: FILE?,I;)
`912532014
`
`_
`LS. i‘)iS“I“Rfl{'T C‘(JUR'i“
`for the DISIITICI of Delaware
`
`I")IZFiiNDANT
`AGILA SPECIALTIES INC. ffkla STRIDES, INC.. and
`ONCO THERAPIES LIMITED
`
`TRU
`I 8.791.270
`
`T’f29:’201-*-I
`
`H0L.L)i:'R OI" I‘A'l‘iiN'1' DR ’l‘R.-*s1)i;'I\viAi{I<.
`CEPHALON. INC.
`
`R
`
`
`UK ‘I R.i\.I.)liI‘v‘I.~\RK
`l‘)E’:§].{} l"‘)" ("l._I‘:'RK
`
`I‘3:‘\VIVI3. INC] .I.N.?i)I”§I)
`
`I’/\'H‘..\I”I\ UR
`IVI{:\[)IEN'If\IiI( NU.
`
`I)./‘(I If UI" I‘1\I‘I’5NEI
`
`C] (.7i‘ms Iiili
`
`C] Uiiicr I’lc':::dim_z
`
`in me ;.iI'3i‘I\‘rZ‘
`
`emiilcd cmre. (he i‘nIluv.‘ing dccisiun I135 been remiered ni'jud~__~e|n::11i ismmi,
`
`I)I".(“I§.\7l("3,’\%}L~ If’){i E:S2z\\'I1 I:T\IT
`
`('I.I".I{K
`
`I 8'1’ I
`
`(Topy I——-~l.‘pon initiation ml‘ action. mail this cop) to llirvcmr Copy 3-~-»~Up0I1 termination ofactimi. mail this copy to Dirt-c‘Inr
`Copy 1»»»»»»»-Il pun filing document adding palentis). mail this copy to Director Copy 4-——~(,‘:1se fiie copy
`
`0002
`
`0002
`
`

`
`Case 1:14—cv-01238—GMS Document 4 Filed 09/25/14 Page 1 of 1 PageID #: 47
`
`M’; 13%.’! «Rm 0% In
`
`TRA]:)[j[\1'A[{‘{(
`
`REl’()RT ON THE
`FIEJNG on DE‘I‘ERMlNA’l‘l0N or AN
`ACTION REGARDING A PATENT OR
`
`"“‘
`
`Mail Stop 8
`ume.-m.- M" the us. me.“ and Tmdemark Office
`(£0. Box [450
`.Me7\‘andI'ia, VA 223$}-I450
`
`1 Ha you are éucrcby zsduwzcfi than a mum zactiun has. Mm
`E
`In (;‘ump§i-arm: \H1h ES Lf.$,(‘. :3 390 mdror E5 l.¥.S.('. {i
`Him} in We
`Ihslrim (Shun
`for the District Of Delaware
`an the fnllvwéng
`
`D Tl'.*".\tl¢.T51'!£\lI'kS- my
`
`EP:1Lcr1ts,
`
`( E] the: pale!!! zwlinn im<»i~ac.»< 35 U.!*?.('.
`
`293,):
`
`i.)(i)L'KEC!' MI),
`
`P L A E NT [F F
`CEPHALON. INC.
`
`DATI: FJLEW)
`9f25.‘20’l4
`
`iT)!S'i'RlC"T“ L‘CIL7RT
`for the District of Delaware
`
`D f?.i*'§"-’. N U A T
`INNOPHARMA. WC.
`
`P.~”«.1"f?',‘~€"1 OR
`.]..RM.)FNMRK NU.
`
`D,~=\TI{ CJF P:‘\TE:“§T
`DR TRADKMARK
`
`0.
`V
`.
`,.
`.
`...\
`.
`.
`A.
`HULDLR (Mr PA I }:NI UR IR.-’\Dl:MAl{}~.
`
`1 8,791,270
`
`?i29a'2014
`
`CEPHALON. iNC.
`
`D.»‘\‘I’!i H\'(f’1.LFD!"l)
`
`P./\ I !:‘.‘«€’I UR
`I R.~\{_H‘::?\1:'\]{K NU.
`
`i).»"H i:. ()t" E‘.~‘H'l:N I
`UK /3 §<.’\[:3t§f\‘l.»KR}K
`
`E} (Wm-ls‘ Hili
`
`E] “HWY Vlcanlirzg
`
`In 11w nlmve
`
`enaitled came. the fmlmving decmim: has been rendv.~:=red nrjmlgexnelxt i:~.sm‘:d..
`
`iT)F.("§§?+l(7)?‘-*’ .lLFDCiE%.?v1}‘.?\5T
`
`
`
`(HY) lJH’U YY (‘LH{K
`
`(Top) 3-~»Upm1 tcrminaritm ofzmtima. mail this cup§ to Dirvecmr
`(Tnpy I ———————~ L pun initiation 0l'actim1.mail this copy to [Jim-cmr
`Copy 2 ~~~~~~ Lpon filing mxmxnlem adding pmcntts). mail this copy to [Director
`C.‘.op_\~ 4---------«Case fife cupy
`
`0003
`
`0003
`
`

`
`Case 1:13-cv-02046-GMS Document 35 Filed 11/06/14 Page 1 of 1 PagelD #2 362
`A0 120 (Rev. 08/10
`
` Mail Stop 8
`
`T0:
`
`DuwmrMflmUSJmmamHmkmmkOfike
`P.0. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FHJNG(MRDETERNHNATHNVOFAN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`A
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the US. District Court
`for the District of Delaware
`on the following
`(
`1:} Trademarks or
`[2IPatents.
`|:] the patent action involves 35 U.S.C. § 292.):
`DOCKET NO.
`DATE FILED
`U.S. DISTRICT COURT
`13—2046—GMS
`12/19/2013
`for the District of Delaware
`PLAINTIFF
`
`»
`
`DEFENDANT
`
`HOLDER OF PAIENT OR TRADEMARK
`
`CEPHALON, lNC.
`
`HETERO LABS LTD. and HETERO USA, INC.
`
`PATENT OR
`TRADEMARK NO‘
`
`DATE OF PATENT
`OR TRADEMARK
`
`., ,.
`
`.
`
`DATE INCLUDED
`1 1/6/2014
`PATENT OR
`TRADEMARK NO.
`
`In the above~—entitled case, the following patcnt(s)/ trademark(s) have been included:
`INCLUDED BY
`
`[21 Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`E] Answer
`
`[:1 Cross Bill
`
`[:1 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 US 8,791,270 B2
`
`7/29/2014
`
`Cephalon, lnc.
`
`———— I
`
`n the abovementitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`(BY) DEPUTY CLERK
`
`Copy l——Upon initiation of action, mail this copy to Director Copy 3——Upon termination of action, mail this copy to Director
`Copy 2-—L'pon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0004
`
`0004
`
`

`
`Case 1:14-cv-01332-UNA Document 4 Filed 10/21/14 Page 1 of 1 PageID #: 148
`
`A0 120 Rev. 08/10
`
`TRADEMARK
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`To
`'
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`District of Delaware
`on the following
`
`I:] Trademarks or
`
`IZPatents.
`
`( E] the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`10/21/2014
`
`U.S. DISTRICT COURT
`
`District of Delaware
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`WOCKHARDT BIO LTD., WOCKHARDT LTD., and WOCKHARDT USA, LLC
`
`DEFENDANT
`
`——
`
`DATE INCLUDED
`
`In the above——entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`CI Amendment
`
`[:I Answer
`
`I] Cross Bill
`
`[3 Other Pleading
`
`HOLDER or PATENT OR TRADEMARK
`%’;T¥R(fD1;:’:ATE:I:
`Tfiggmfio
`_——
`——
`——
`——
`——
`
`
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`
`
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3———Upon termination of action, mail this copy to Director
`Copy 2——Upon filing document adding patent(s), mail this copy to Director Copy 4~—Case file copy
`
`0005
`
`0005
`
`

`
`Case 1:14—cv-01117—GMS Document 10 Filed 10/03/14 Page 1 of 3 PagelD #: 151
`
`Case 1:14—cv-01117—GMS Document 4 Filed 09/02/14 Page 1 of 1 PagelD #: 144
`A0 I20 Rev. 08/10
`
` REPORT ON THE
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`PO. Box 1450
`
`Alexandria, VA 22313-1450
`
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`District of Delaware
`on the following
`
`El Trademarks or
`
`[Z Patents.
`
`( I] the patent action involves 35 U.S.C. §292.):
`
`DOCKET NO.
`
`PLAINTIFF
`
`DATE FILED
`9/2/2014
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`District of Delaware
`
`CEPHALON, INC.
`
`NANG KUANG PHARMACEUTICAL CO., LTD. and
`CANDA NK-1, LLC
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`5/21/2013
`
`5/7/2013
`
`12/17/2013
`
`7/29/2014
`
`DATE INCLUDED
`
`INCLUDED BY
`
`[J Amendment
`
`C] Answer
`
`1:] Cross Bill
`
`C] Other Pleadin
`
`HOLDER OF PATENT OR TRADEMARK
`
`
`
`In the above—entitled case, the following decision has been rendered orjudgement issued:
`DECISION/JUDGEMENT
`
`CLERK United
`844
`
`tate Dsrict Court
`King Street. Unit 18
`. U
`
`Copy l——-—Upon initiation of action, mail this copy to Direc r
`Copy 3—Upon termination of action. mail this copy to Director
`Copy 2-—Upon filing document adding patent(s), mail this copy to Director
`Copy 4——Case file copy
`
`0006
`
`0006
`
`

`
`Case 1:13—cv—02095—GMS Document 29 Filed 09/18/14 Page 1 of 1 Page|D #: 454
`
`A0 120 Rev. 08/10
`
`TO.
`'
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`TRADEMARK
`
`Alexandria, VA 22313-1450
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`for the District of Delaware
`on the following
`
`I] Trademarks or
`
`lZPatents.
`
`( El the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`13-2095—GMS
`PLAINTIFF
`
`
`
`
`
`
`DATE FILED
`9/18/2014
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`ACCORD HEALTHCARE, INC. and INTAS
`
`
`
`
`
`
`CEPHALON, INC.
`
`PHARMACEUTICALS LTD.
`
`
`
`
`
`
`
`——
`——
`
`
`
`In the above—entitled case, the following patent(s)/ trademaIk(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENT OR
`
`M Amendment
`DATE OF PATENT
`
`E] Answer
`
`[:1 Cross Bill
`
`D Other Pleading
`
`WW
`
`1 8,791,270
`
`7/29/2014
`
`CEPHALON, INC.
`
`
`
`———_
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`
` (BY) DEPUTY CLERK
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4——Case file copy
`
`0007
`
`0007
`
`

`
`Case 1:14-cv-01116-UNA Document 4 Filed 09/02/14 Page 1 of 1 Page|D #: 149
`A0 120 Rev. 08/10
`
`TRADEMARK
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Coufl
`District of Delaware
`on the following
`
`I:l Trademarks or
`
`[ZPatents.
`
`( [:I the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`PLAINTIFF
`
`DATE FILED
`9/2/2014
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`District of Delaware
`
`
`
`CEPHALON, INC.
`
`SAGENT PHARMACEUTICALS, INC. and
`SAGENT AGILA LLC
`
`
`
`
`
`
`
`
`
`
`
`
`‘—
`
`
`
`DATE INCLUDED
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`INCLUDED BY
`
`[I Answer
`
`B Cross Bill
`
`[:1 Other Pleading
`
`I
`
`[] Amendment
`PATENT OR
`DATE OF PATENT
`TRADEMARK NO.
`OR TRADEMARK
`HOLDER OF PATENT OR TRADEMARK
`———
`——
`——
`-—
`
`——
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy l—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—-Case file copy
`
`0008
`
`
`
`0008
`
`

`
`Case 1:14-cv-01117—UNA Document 4 Filed 09/02/14 Page 1 of 1 Page|D #: 144
`
`A0 120 Rev. 08/10
`
`TRADEMARK
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.0. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court
`District Of Delaware
`on the following
`
`D Trademarks or M Patents.
`
`( El the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`9/2/2014
`
`U.S. DISTRICT COURT
`
`District of Delaware
`
`
`
`
`
`
`PLAINTIFF
`
`CEPHALON, INC.
`
`PATENT OR
`TRADEMARK NO.
`
`
`
`
`
`DEFENDANT
`
`NANG KUANG PHARMACEUTICAL CO., LTD. and
`CANDA NK—1, LLC
`
`HOLDER OF PATENT ORTRADEMARK
`
`
`
`j I
`
`n the above—entit1ed case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`
`
`E] Answer
`CI Cross Bill
`[3 Other Pleading
`HOLDER OF PATENT OR TRADEMARK
`
`I:I Amendment
`%’:3:R(?\FDI;:’;4TflI:I:
`TRESEEAPJIRERNO
`1 —
`—
`
`
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`
`(BY) DEPUTY CLERK
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2——-Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`0009
`
`0009
`
`

`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`13/969,724
`
`ISSUE DATE
`
`07/29/2014
`
`46347
`
`7590
`
`07/09/2014
`
`Baker & Hostetler LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`8791270
`
`102085.004604
`
`6392
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above—identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above—identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto. gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(S) (Please see PAIR WEB site http://pair.uspto. gov for additional applicants):
`
`Cephalon, Inc., Frazer, PA, Assignee (with 37 CFR 1.172 Interest);
`Jason Edward Brittain, El Cajon, CA;
`Joe Craig Franklin, Tulsa, OK, Deceased;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`0010
`
`0010
`
`

`
`Receipt date: 12/18/2013
`
`13969724 ~ GAL}: 1617
`
`Substitute for Form 1449/PTO
`
`INFORMATION DISCLOSURE
`
`Complete if Known
`13/969724
`
`
`
`STATEMENT BY APPLICANT
`
`Jason Edward Brittain
`1617
`Soroush-A'i
`If CEPH-4604/CP391D U8
`
`(use as many sheets as necessary)
`
`U. S. PUBLICATION AND PATENT DOCUMENTS
`Publication or
`Document Number
`
`Examiner
`Initials
`
`-
`
`Number— Kind Code (If known)
`
`_
`
`_
`/,c\‘3_,/ 3 5,130,305A
`26
`5,183,746 A
`27
`5,192,743 A
`28
`5,204,335 A
`29
`5,227,373 A
`5,227,374 A
`5,268,368 A
`5,413,995 A
`5,418,223A
`5,750,131 A
`5,770,230A
`5,776,456A
`5,955,504 A
`5,972,912 A
`
`Grant Date
`07-14-1992
`02-02-1993
`03-09-1993
`04-20-1993
`07-13-1993
`07-13-1993
`12-07-1993
`05-09-1995
`05-23-1995
`05-12-1998
`06-23-1998
`07-07-1998
`09-21-1999
`10-26-1999
`
`MM_DD_WW
`
`03-07-2000
`
`Name ofPatentee orApplicantofCited Document
`Palepu etal.
`Shaked et al.
`Hsu et al.
`Sauerbier et al.
`Alexander et al.
`Alexander et al.
`Palepu
`Alexander et al.
`Palepu etal.
`Wichert et al.
`Teagarden etal.
`Anderson et al.
`Wechter et al.
`Marek et al.
`
`Maeienser Carters-tal.
`
`06-20-2000
`
`Maefefi-efi Cartcrct aI.
`
`07-18-2000
`
`08-07-2001
`04-30-2002
`12-12-2002
`04-08-2003
`05-27-2003
`06-03-2003
`09-02-2003
`
`Kaminski etal.
`
`Mae-feH=e-F Carterctal.
`Desimone etal.
`Maefenrer Cartere’caI.
`Carson et al.
`Cheesman etal.
`Nardella
`Kwok
`
`38
`
`39
`
`41
`
`6,034,256A
`
`6,077,850 A
`
`6,090,365A
`
`40
`
`to cIoc-u-me,
`.
`E,
`
`(V T‘
`
`Cu
`
`F23v
`
`I
`
`/GK.
`
`6/25
`
`20,‘, 6,271,253 B1
`6,380,210 B1
`6,492,390 B2
`6,545,034 B1
`6,569,402 B1
`6,573,292 B1
`. M 6,613,927 B1
`
`
`
` Examiner
`06/01/2014
`
`/Ali Soroush/’
`
`Sinature
`
`0011
`
`0011
`
`

`
`Receipt date: 32/18/2013
`
`‘$396?/"24 ~ GAL}: 1617
`
`Substitute for Form 1449/PTO
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`(use as many sheets as necessary)
`
`If CEPH-4604/CP391D US
`
`Complete if Known
`13/969-724
`
`Jason Edward Brittain
`1617
`Sorouswi
`
`U. S. PUBLICATION AND PATENT DOCUMENTS
`
`Examiner
`Cite
`Document Number
`'"i“3'S
`N0-
`Number— Kind Code (if known)
`/'A-»/ Q 2002/0102215 A1
`2003/0232874 A1
`
`PII3II:IaI(r:1ItaIID0aIIt<=f)r
`MM_DD_WW
`08-01-2002
`12-18-2003
`
`Name of Patentee or A |'cant of C'ted Doc ment
`ppl
`I
`U
`
`Klaveness et al.
`Nardella
`
`
`
`14
`
`15
`
`16
`17
`
`_. Q Q an
`
`Ck
`an ‘
`d
`to oum t
`/G.Kr>./
`6/25 201
`
`’
`
`
`2004/0053972 A1
`
`03-18-2004
`
`Nara
`
`2004/0058956 A1
`2004/0072889 A1
`2004/0096436 A1
`2004/0152672 A1
`2004/0247600 A1
`2005/0020615 A1
`2005/0060028 A1
`2005/0176678 A1
`2006/0051412 A1
`2006/0128777 A1
`2009/0264488 A1
`
`2011/0190363 A1
`
`2012/0071532 A1
`2013/0041003 A1
`2013/0123316 A1
`3,590,028 A
`4,012,448A
`4,537,883 A
`4,659,699 A
`4,670,262 A
`5,066,647A
`
`03-25-2004
`04-15-2004
`05-20-2004
`08-05-2004
`12-09-2004
`01-27-2005
`03-17-2005
`08-11-2005
`03-09-2006
`06-15-2006
`10-22-2009
`
`Akiyama et al.
`Masferrer
`Carson et al.
`Carson et al.
`Leoni
`Rubino
`Horres et al.
`Horres et al.
`Petereit et al.
`Bendall etal.
`Cooper et al.
`
`08-04-2011
`
`Drager et al.
`
`03-22-2012
`cooper et al.
`02-14-2013 . Epnttam etaI
`05-16-2013
`Brittain
`06-29-1971
`Report etal.
`03-15-1977
`Smith etal.
`08-27-1985
`Alexander et al.
`04-21-1987
`Francis
`06-02-1987
`Battelli et al.
`11-19-1991
`Palepu etal.
`
`Examiner
`
`/Aié Soroush/' Sinature
`06/01/2014
`
`Date
`
`,
`
`0012
`
`0012
`
`

`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or 1 (571)-273-2885
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`in icated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any Change Ofaddress)
`
`7590
`46347
`Baker & HOSt6tl6I‘ LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`
`06/09/2014
`
`PHILADELPHIA, PA 19104-2891
`
`Note: A certificate of mailin can only be used for domestic mailings of the
`Fee(s) Transmittal. This certi icate cannot be used for any other accompanying
`fiapers. Each additional paper, such as an assignment or formal drawing, must
`ave its own certificate of mailing or transmission.
`
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`States Postal Service with sufficient postage for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`
`(Date)
`
`‘D°P°s“°"“““‘°>
`(Signature)
`
`APPLICATION NO.
`
`FILING DATE
`
`F {ST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`Jason Edward Brittain
`08/19/2013
`13/969,724
`TITLE OF INVENTION: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`102085.004604
`
`6392
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`SOROUSH, ALI
`
`$960
`
`1617
`
`$0
`
`$0
`
`$960
`
`09/09/2014
`
`548-304700
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR1_363)_
`3 Chan e of correspondence address (or Change of Correspondence
`Address orm PTO/SB/ 122) attached.
`
`3 "Fee Address" indication (or "Fee Address" Indication form
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Vumber is required.
`
`2. For printing on the patent front page, list
`(1) The names of up to 3 registered patent attorneys
`or agents OR, alternatively,
`(2) The name of a single firm (having as a member a
`registered attorney or agent) and the names of up to
`2 registered patent attorneys or agents. If no name is
`listed, no name will be printed.
`
`
`
`-
`1 _3aker & Hostetler LLP
`
`2
`
`3
`
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`If an assignee is identified below, the document has been filed for
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent.
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`CEPHALON,
`
`INC.
`
`l:RA7.*.R, P*.NNSYT.\/ANIA
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) :
`
`'3 Individual E Corporation or other private group entity '3 Government
`
`4a. The following fee(s) are submitted:
`3 Issue Fee
`3 Publication Fee (No small entity discount permitted)
`3 Advance Order — # of Copies
`
`5. Change in Entity Status (from status indicated above)
`3 Applicant certifying micro entity status. See 37 CFR 1.29
`
`3 Applicant asserting small entity status. See 37 CFR 1.27
`
`3 Applicant changing to regular undiscounted fee status.
`
`4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)
`3 A check is enclosed.
`3 Payment by credit card. Form PTO-2038 is attached.
`3 The Director is hereby authorized to charge t§e3re%1'5e§6ee(s), any deficiency, or credits any
`overpayment, to Deposit Account Number
`(enclose an extra copy of this form).
`
`\IOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/ 15A and 15B), issue
`fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
`\IOTE: If the application was previously under micro entity status, checking this box will be taken
`to be a notification of loss of entitlement to micro entity status.
`\IOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable.
`
`NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature reguirements and certifications.
`
`Authorized Signature /Stephanie A. Lodise/
`Ste han'e A. Lod'se
`p
`l
`1
`
`Typed or printed name
`
`Date
`
`June 12 ,
`
`2 0 1 4
`
`Registration No.
`
`5 1 4 3 0
`
`PTOL—85 Part B (10-13) Approved for use through 10/31/2013.
`
`OMB 0651-0033
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF CE
`
`Page 2 of 3
`
`0013
`
`

`
`Electronic Patent Application Fee Transmittal
`
`Title oflnventionz
`
`BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`First Named Inventor/Applicant Name:
`
`Jason Edward Brittain
`
`Attorney Docket Number:
`
`102085.004604
`
`Utility under 35 USC111(a) Filing Fees
`
`Description
`
`Fee Code
`
`Quantity
`
`Sub-Total in
`
`USD($)
`
`Basic Filing:
`
`Miscellaneous-Filing:
`
`Patent-Appeals-and-Interference:
`
`Post-AlIowance-and-Post-Issuance:
`
`0014
`
`0014
`
`

`
`Miscellaneous:
`
` S“:-S1-;(t$a)| in
`
`Total in USD (S)
`
`0015
`
`0015
`
`

`
`Electronic Acknowledgement Receipt
`
`m—
`
`Title oflnventionz
`
`BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`I
`
`Payment information:
`
`yes—
`Submitted with Payment
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)
`
`—Auth°“zedUser
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)
`
`0016
`
`0016
`
`

`
`Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)
`
`FHeLBfing:
`
`Document
`
`Information:
`
`Information:
`
`.
`
`.
`
`File Size(Bytes)/
`
`Multi
`
`Pages
`
`Issue Fee Payment (PTO-85B)
`
`Issue_fee_transmitta|.PDF
`
`e3cd2bbabd345f6617eca8ff1e7acf801cd1
`4eaa
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`I 081 I b2782fdl ld64763 I 802e57l 3el f867 ‘
`f6a9
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`lfa new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`lfa timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`lfa new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and ofthe International Filing Date (Form PCT/R0/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`0017
`
`0017
`
`

`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`46347
`
`7590
`
`06/09/2014
`
`Baker & Hostetler LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`PHILADELPHIA, PA 19104-2891
`
`SOROUSH, ALI
`
`1517
`
`DATE MAILED: 06/09/2014
`
`Jason Edward Brittain
`08/19/2013
`13/969,724
`TITLE OF INVENTION: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`102085004604
`
`6392
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`09/09/2014
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED.
`SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLY TO THIS NOTICE:
`
`I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify Whether entitlement to that
`entity status still applies.
`
`If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`
`If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled
`"Change in Entity Status (from status indicated above)".
`
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity
`fees.
`
`II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalent of Part B.
`
`III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advised to the contrary.
`
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL—85 (Rev. 02/11)
`
`Page 1 of 3
`
`0018
`
`0018
`
`

`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or 1 (571)-273-2885
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`in icated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any Change Ofaddress)
`
`7590
`46347
`Baker & HOSt6tl6I‘ LLP
`CIRA CENTRE, 12TH FLOOR
`2929 ARCH STRET
`
`06/09/2014
`
`PHILADELPHIA, PA 19104-2891
`
`Note: A certificate of mailin can only be used for domestic mailings of the
`Fee(s) Transmittal. This certi icate cannot be used for any other accompanying
`fiapers. Each additional paper, such as an assignment or formal drawing, must
`ave its own certificate of mailing or transmission.
`
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`States Postal Service with sufficient postage for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`
`(Date)
`
`‘D°P°s“°"“““‘°>
`(Signature)
`
`APPLICATION NO.
`
`FILING DATE
`
`F {ST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`Jason Edward Brittain
`08/19/2013
`13/969,724
`TITLE OF INVENTION: BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
`
`102085.004604
`
`6392
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE
`
`PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`SOROUSH, ALI
`
`$960
`
`1617
`
`$0
`
`$0
`
`$960
`
`09/09/2014
`
`548-304700
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`
`3 Chan e of correspondence address (or Change of Correspondence
`Address orm PTO/SB/ 122) attached.
`
`3 "Fee Address" indication (or "Fee Address" Indication form
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Vumber is required.
`
`
`
`2. For printing on the patent front page, list
`(1) The names of up to 3 registered patent attorneys
`or agents OR, alternatively,
`